Zura Bio Ltd expected to post a loss of 15 cents a share - Earnings Preview
06/05/2025 11:33
Zura Bio Ltd ZURA.OQ ZURA.O is expected to show no change in quarterly revenue when it reports results on May 8 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Zura Bio Ltd is for a loss of 15 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Zura Bio Ltd is $11.00, above its last closing price of $1.44. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.16 | -0.10 | Beat | 35.6 | |
| Sep. 30 2024 | -0.12 | -0.12 | -0.26 | Missed | -110.8 |
| Jun. 30 2024 | -0.16 | -0.15 | -0.17 | Missed | -13.5 |
| Mar. 31 2024 | -0.22 | -0.23 | -0.02 | Beat | 91.4 |
| Dec. 31 2023 | -0.23 | -0.19 | Beat | 17.5 | |
| Sep. 30 2023 | -0.25 | -0.25 | -0.18 | Beat | 27.4 |
| Jun. 30 2023 | -0.23 | -0.25 | -1.31 | Missed | -431.1 |
Recent news on Zura Bio
See all newsZura Bio Ltd reports results for the quarter ended June 30 - Earnings Summary
Zura Bio Q2 net loss widens as R&D expenses rise
Zura Bio Ltd expected to post a loss of 20 cents a share - Earnings Preview
Brief: Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zura Bio Expands Leadership Team With Appointment Of Muzammil Mustufa As Chief Business Officer